Samarangenin_NP B_NP from_IN Limonium_NP sinense_NN Suppresses_NP Herpes_NP Simplex_NP Virus_NP Type_NP 1_CD Replication_NN in_IN Vero_NP Cells_NP by_IN Regulation_NP of_IN Viral_NP Macromolecular_NP Synthesis_NP Inhibitory_NP effects_NNS of_IN ethanolic_NN extracts_VBZ from_IN 10_CD Chinese_JJ herbs_NNS on_IN herpes_NN simplex_JJ virus_NN type_NN 1_CD (_( HSV-1_NP )_) replication_NN were_VBD investigated_VBN ._SENT By_IN a_DT bioassay-guided_JJ fractionation_NN procedure_NN ,_, samarangenin_NP B_NP (_( Sam_NP B_NP )_) was_VBD isolated_VBN from_IN Limonium_NN sinense_NN ;_: Sam_NP B_NP significantly_RB suppressed_VBD HSV-1_JJ multiplication_NN in_IN Vero_NP cells_NNS without_IN apparent_JJ cytotoxicity_NN ._SENT Time-of-addition_NN experiments_NNS suggested_VBD that_IN the_DT inhibitory_JJ action_NN of_IN Sam_NP B_NP on_IN HSV-1_NP replication_NN was_VBD not_RB due_JJ to_TO the_DT blocking_VBG of_IN virus_NN adsorption_NN ._SENT In_IN an_DT attempt_NN to_TO further_RBR localize_VB the_DT point_NN in_IN the_DT HSV-1_NP replication_NN cycle_NN where_WRB arrest_NN occurred_VBD ,_, a_DT set_NN of_IN key_JJ regulatory_JJ events_NNS leading_VBG to_TO viral_JJ multiplication_NN was_VBD examined_VBN ,_, including_VBG viral_JJ immediate-early_RB (_( alpha_NN )_) ,_, early_RB (_( beta_NN )_) ,_, and_CC late_RB (_( gamma_NN )_) gene_NN expression_NN and_CC DNA_NN replication_NN ._SENT Results_NNS indicated_VBD that_IN levels_NNS of_IN glycoprotein_NN B_NP (_( gB_NN )_) ,_, gC_NN ,_, gD_NNS ,_, gG_NN ,_, and_CC infected-cell_NN protein_NN 5_CD (_( ICP5_NP )_) expression_NN and_CC gB_NN mRNA_NN expression_NN in_IN Vero_NP cells_NNS were_VBD impeded_VBN by_IN Sam_NP B._NP Data_NP from_IN PCR_NP showed_VBD that_DT replication_NN of_IN HSV-1_NP DNA_NP in_IN Vero_NP cells_NNS was_VBD arrested_VBN by_IN Sam_NP B._NP Furthermore_NP ,_, Sam_NP B_NP decreased_VBD DNA_NN polymerase_NN ,_, ICP0_NP ,_, and_CC ICP4_NP gene_NN expression_NN in_IN Vero_NP cells_NNS ._SENT Results_NNS of_IN an_DT electrophoretic_JJ mobility_NN shift_NN assay_NN demonstrated_VBD that_IN Sam_NP B_NP interrupted_VBD the_DT formation_NN of_IN an_DT alpha-trans-induction_NN factor/C1/Oct-1/GARAT_NN multiprotein_NN complex_NN ._SENT The_DT mechanisms_NNS of_IN antiviral_JJ action_NN of_IN Sam_NP B_NP seem_VBP to_TO be_VB mediated_VBN ,_, at_IN least_JJS in_IN part_NN ,_, by_IN inhibiting_VBG HSV-1_JJ alpha_NN gene_NN expression_NN ,_, including_VBG expression_NN of_IN the_DT ICP0_NP and_CC ICP4_NP genes_NNS ,_, by_IN blocking_VBG beta_JJ transcripts_NNS such_JJ as_IN DNA_NP polymerase_NN mRNA_NN ,_, and_CC by_IN arresting_VBG HSV-1_NP DNA_NP synthesis_NN and_CC structural_JJ protein_NN expression_NN in_IN Vero_NP cells_NNS ._SENT These_DT results_NNS show_VBP that_IN Sam_NP B_NP is_VBZ an_DT antiviral_JJ agent_NN against_IN HSV-1_JJ replication_NN ._SENT Herpes_NN simplex_JJ virus_NN type_NN 1_CD (_( HSV-1_NP )_) is_VBZ an_DT enveloped_VBN DNA_NN virus_NN which_WDT causes_VBZ a_DT variety_NN of_IN infections_NNS in_IN humans_NNS ._SENT After_IN primary_JJ infection_NN ,_, HSV-1_NP establishes_VBZ latency_NN in_IN sensory_JJ and_CC autonomic_JJ neurons_NNS innervating_VBG the_DT mucosal_JJ tissues_NNS ,_, where_WRB primary_JJ infection_NN takes_VBZ place_NN ,_, and_CC is_VBZ reactivated_VBN by_IN the_DT proper_JJ stimulus_NN to_TO cause_VB recurrence_NN ._SENT The_DT period_NN of_IN recurrence_NN is_VBZ irregular_JJ ._SENT Immunocompromised_JJ individuals_NNS and_CC those_DT with_IN cancer_NN are_VBP in_IN danger_NN of_IN recurrent_JJ HSV-1_JJ infections_NNS ._SENT The_DT recipients_NNS of_IN organ_NN transplantation_NN are_VBP at_IN high_JJ risk_NN for_IN increased_VBN severity_NN of_IN HSV-1_JJ infection_NN ._SENT Infection_NN with_IN HSV-1_NP can_MD lead_VB to_TO life-threatening_JJ encephalitis_NN and_CC ocular_JJ infections_NNS that_WDT result_VBP in_IN corneal_JJ inflammation_NN and_CC scarification_NN ._SENT This_DT scarification_NN is_VBZ a_DT major_JJ cause_NN of_IN blindness_NN in_IN developing_VBG countries_NNS ._SENT In_IN addition_NN ,_, HSV-1_NP has_VBZ been_VBN shown_VBN to_TO be_VB a_DT factor_NN for_IN spreading_VBG human_JJ immunodeficiency_NN virus_NN and_CC causes_VBZ severe_JJ diseases_NNS in_IN AIDS_NP patients_NNS ._SENT One_CD successful_JJ replication_NN cycle_NN of_IN HSV-1_NP is_VBZ dependent_JJ on_IN the_DT completion_NN of_IN a_DT number_NN of_IN steps_NNS ,_, including_VBG virion_NN entry_NN ,_, subsequent_JJ expression_NN of_IN viral_JJ immediate-early_JJ (_( alpha_NN )_) genes_NNS such_JJ as_IN infected-cell_NN protein_NN 0_CD (_( ICP0_NP )_) and_CC ICP4_NP genes_NNS ,_, early_RB (_( beta1_JJ and_CC beta2_JJ )_) genes_NNS including_VBG DNA_NN polymerase_NN and_CC thymidine_NN kinase_NN genes_NNS ,_, and_CC late_RB (_( gamma1_JJ and_CC gamma2_JJ )_) genes_NNS encoding_VBG glycoprotein_NN B_NP (_( gB_NN )_) ,_, ICP5_NP ,_, and_CC gC_NN ,_, and_CC unpaired_JJ DNA_NN replication_NN ._SENT The_DT initial_JJ expression_NN of_IN HSV-1_JJ alpha_NN genes_NNS depends_VBZ on_IN the_DT binding_NN of_IN the_DT alpha_NN trans-induction_NN factor_NN (alphaTIF)/C1/Oct-1_JJ multiprotein_NN complex_JJ to_TO the_DT TAAGARAT_NP (_( R_NP ,_, purine_NN ;_: GARAT_NP )_) sequences_NNS of_IN the_DT cis-acting_JJ site_NN ._SENT Inhibition_NN of_IN any_DT of_IN these_DT stages_NNS blocks_VBZ HSV-1_JJ replication_NN ._SENT Nucleoside_NN analogues_NNS have_VBP been_VBN extensively_RB investigated_VBN in_IN the_DT search_NN for_IN effective_JJ antiherpesvirus_NN agents_NNS ._SENT Among_IN these_DT acyclovir_NN is_VBZ widely_RB used_VBN for_IN the_DT systemic_JJ treatment_NN of_IN HSV_NP infections_NNS ._SENT It_PP is_VBZ a_DT highly_RB selective_JJ antiviral_JJ agent_NN because_IN it_PP is_VBZ specifically_RB phosphorylated_JJ by_IN viral_JJ thymidine_NN kinase_NN in_IN infected_JJ cells_NNS ._SENT However_RB ,_, acyclovir-resistant_JJ HSV_NP infection_NN in_IN immunocompromised_JJ patients_NNS such_JJ as_IN transplant_NN patients_NNS and_CC patients_NNS with_IN AIDS_NP has_VBZ recently_RB been_VBN observed_VBN ._SENT Therefore_RB ,_, it_PP is_VBZ desirable_JJ to_TO develop_VB new_JJ anti-HSV_NP agents_NNS that_WDT substitute_VBP for_IN or_CC complement_VB acyclovir_NN ._SENT Chinese_JJ herbs_NNS are_VBP potential_JJ sources_NNS of_IN useful_JJ edible_JJ and_CC medicinal_JJ plants_NNS ._SENT They_PP are_VBP expected_VBN to_TO find_VB use_NN as_IN functional_JJ foods_NNS because_IN of_IN their_PP$ various_JJ biological_JJ activities_NNS such_JJ as_IN immunomodulatory_NN and_CC antitumor_NN functions_NNS ._SENT More_JJR and_CC more_JJR people_NNS in_IN developing_VBG countries_NNS utilize_VB traditional_JJ medicine_NN for_IN their_PP$ major_JJ primary_JJ health_NN care_NN needs_VBZ ._SENT However_RB ,_, ethnopharmacology_NN also_RB provides_VBZ scientists_NNS with_IN an_DT alternative_JJ approach_NN for_IN the_DT discovery_NN of_IN antiviral_JJ agents_NNS ._SENT The_DT polysaccharides_NNS ,_, anthraquinones_NNS ,_, triterpenes_NNS ,_, phloroglucinol_NN ,_, flavonoids_NNS ,_, and_CC catechin_NN derivatives_NNS isolated_VBN from_IN medicinal_JJ plants_NNS have_VBP been_VBN found_VBN to_TO have_VB inhibitory_JJ activities_NNS against_IN the_DT replication_NN of_IN HSV-1_NP ._SENT There_EX has_VBZ been_VBN a_DT promising_JJ result_NN for_IN a_DT naturally_RB occurring_VBG antiherpetic_NN agent_NN ,_, n-docosanol_NP ,_, which_WDT has_VBZ recently_RB completed_VBN extensive_JJ clinical_JJ evaluation_NN and_CC been_VBN approved_VBN by_IN the_DT U.S._NP Food_NP and_CC Drug_NP Administration_NP as_IN a_DT topical_JJ treatment_NN for_IN herpes_NN labialis_NNS ._SENT These_DT findings_NNS show_VBP that_IN natural_JJ products_NNS are_VBP still_RB potential_JJ sources_NNS in_IN the_DT search_NN for_IN new_JJ antiherpetic_NN agents_NNS ._SENT In_IN the_DT present_JJ study_NN ,_, 10_CD Chinese_JJ herbs_NNS which_WDT are_VBP widely_RB known_VBN in_IN folk_NN medicine_NN for_IN the_DT treatment_NN of_IN viral_JJ and_CC bacterial_JJ infection_NN were_VBD selected_VBN for_IN an_DT anti-HSV-1_JJ replication_NN assay_NN ._SENT The_DT herbs_NNS were_VBD Ventilago_NP leiocarpa_NP ,_, Ecdysanthera_NP rosea_NP ,_, Ecdysanthera_NP utilis_NP ,_, Hippobroma_NP longiflora_NP ,_, Ardrisia_NP brevicaulis_NP ,_, Selaginella_NP delicatula_NP ,_, Limonium_NN sinense_NN ,_, Ardrisia_NP japonica_NN ,_, Ardrisia_NP violacea_NP ,_, and_CC Andendron_NP benthamianum_NN ._SENT The_DT ethanolic_NN extracts_VBZ that_WDT showed_VBD appreciable_JJ anti-HSV-1_JJ activity_NN were_VBD separated_VBN by_IN a_DT bioassay-guided_JJ fractionation_NN procedure_NN ._SENT The_DT effect_NN of_IN active_JJ component_NN samarangenin_NN B_NP (_( Sam_NP B_NP )_) ,_, isolated_VBN from_IN L._NP sinense_NN ,_, on_IN HSV-1_JJ alpha_NN ,_, beta_NN ,_, and_CC gamma_NN gene_NN expression_NN and_CC DNA_NN replication_NN in_IN Vero_NP cells_NNS was_VBD evaluated_VBN ._SENT The_DT mechanisms_NNS of_IN antiviral_JJ action_NN of_IN Sam_NP B_NP were_VBD elucidated_VBN in_IN vitro_NN ._SENT Preparation_NN of_IN crude_NN extracts_VBZ for_IN Chinese_JJ herbs_NNS ._SENT |_SYM All_DT 10_CD species_NNS of_IN Chinese_JJ herbs_NNS were_VBD purchased_VBN from_IN Chinese_JJ medicine_NN shops_NNS in_IN Taipei_NP ,_, Taiwan_NP ,_, and_CC were_VBD identified_VBN by_IN Lie-Chwen_NP Lin_NP ._SENT Each_DT dried_VBN Chinese_JJ herb_NN (_( 600_CD g_NN )_) was_VBD extracted_VBN with_IN ethanol_NN (_( three_CD times_NNS in_IN 5_CD liters_NNS )_) ._SENT After_IN solvent_JJ was_VBD removed_VBN ,_, the_DT crude_NN extracts_VBZ were_VBD dissolved_VBN in_IN dimethyl_NN sulfoxide_NN (_( DMSO_NP )_) to_TO a_DT concentration_NN of_IN 100_CD mg/ml_NN and_CC stored_VBN at_IN 4C_JJ until_IN use_NN ._SENT Sam_NP B_NP isolation_NN from_IN L._NP sinense_NN ._SENT |_SYM The_DT method_NN followed_VBD procedures_NNS described_VBD previously_RB ._SENT The_DT ethanolic_NN extract_NN of_IN the_DT dried_VBN roots_NNS of_IN L._NP sinense_NN was_VBD partitioned_VBN in_IN succession_NN between_IN H2O_NP and_CC n-hexane_JJ ,_, followed_VBN by_IN ethyl_NN acetate_NN and_CC n-butanol_JJ (_( n-BuOH_JJ )_) ._SENT The_DT bioactive_JJ n-BuOH_JJ fraction_NN was_VBD subjected_VBN to_TO chromatography_NN on_IN Sephadex_NP LH-20_NP with_IN gradient_JJ methanol-H2O_NN elution_NN (_( from_IN 0_CD to_TO 100_CD %_NN )_) to_TO produce_VB 12_CD fractions_NNS ._SENT Sam_NP B_NP was_VBD identified_VBN from_IN fraction_NN 12_CD and_CC analyzed_VBD with_IN a_DT high-performance_JJ liquid_JJ chromatography_NN (_( HPLC_NP )_) purity_NN program_NN ._SENT It_PP was_VBD dissolved_VBN in_IN DMSO_NP to_TO a_DT concentration_NN of_IN 100_CD mM_NNS and_CC stored_VBN at_IN 4C_JJ until_IN use_NN ._SENT Cell_NN culture_NN and_CC viruses_NNS ._SENT |_SYM Vero_NP cells_NNS were_VBD cultured_VBN in_IN minimal_JJ essential_JJ medium_NN (_( MEM_NP ;_: GIBCO_NP ,_, Grand_NP Island_NP ,_, N.Y._NP )_) supplemented_VBD with_IN 10_CD %_NN fetal_JJ calf_NN serum_NN (_( HyClone_NP ,_, Logan_NP ,_, Utah_NP )_) ,_, 100_CD U_NN of_IN penicillin/ml_NN ,_, and_CC 100_CD mug_NN of_IN streptomycin/ml_NN and_CC incubated_VBN at_IN 37C_JJ in_IN a_DT 5_CD %_NN CO2_JJ incubator_NN ._SENT The_DT cells_NNS were_VBD free_JJ from_IN mycoplasma_NN contamination_NN ,_, which_WDT was_VBD checked_VBN by_IN Mycotect_JJ kit_NN (_( Life_NP Technology_NP ,_, Gaithersburg_NP ,_, Md._NP )_) ._SENT To_TO prepare_VB HSV-1_NP (_( KOS_NP strain_NN )_) stocks_NNS ,_, Vero_NP cells_NNS were_VBD infected_VBN by_IN HSV-1_NP at_IN a_DT multiplicity_NN of_IN infection_NN (_( MOI_NP )_) of_IN 3_CD and_CC harvested_VBN at_IN 24_CD h_NN postinfection_NN (_( p.i._JJ )_) and_CC centrifuged_VBN at_IN 1,500_CD x_NN g_NN (_( CR312_NP ;_: Jouan_NP ,_, Nantes_NP ,_, France_NP )_) at_IN 4C_JJ for_IN 20_CD min_NN ._SENT The_DT supernatant_JJ was_VBD collected_VBN and_CC stored_VBN at_IN -70C_NN for_IN use_NN ._SENT Plaque_NN reduction_NN assay_NN ._SENT |_SYM The_DT assay_NN followed_VBD procedures_NNS described_VBD previously_RB ._SENT Acyclovir_NN was_VBD used_VBN as_IN a_DT positive_JJ control_NN ._SENT Vero_NP cells_NNS (_( 3.5_CD x_SYM 105/dish_JJ )_) were_VBD incubated_VBN with_IN 100_CD PFU_NP of_IN HSV-1_NP ,_, and_CC the_DT test_NN extracts_VBZ or_CC acyclovir_NN was_VBD added_VBN to_TO the_DT cells_NNS at_IN various_JJ concentrations_NNS ._SENT The_DT viruses_NNS were_VBD adsorbed_VBN for_IN 1_CD h_NN at_IN 37C_JJ ,_, and_CC 1_CD %_NN methylcellulose_NN was_VBD added_VBN to_TO each_DT well_NN ._SENT After_IN 5_CD days_NNS ,_, the_DT virus_NN plaques_NNS formed_VBN in_IN Vero_NP cells_NNS were_VBD counted_VBN by_IN crystal_NN violet_NN staining_VBG ._SENT The_DT activities_NNS of_IN test_NN extracts_VBZ and_CC acyclovir_NN for_IN inhibition_NN of_IN plaque_NN formation_NN were_VBD calculated_VBN ._SENT Determination_NN of_IN cell_NN viability_NN ._SENT |_SYM Approximately_RB 3.5_CD x_SYM 105_CD Vero_NP cells_NNS were_VBD cultured_VBN in_IN a_DT 25-cm2_JJ flask_NN and_CC incubated_VBN with_IN 0.1_CD %_NN DMSO_NP or_CC 25_CD muM_NN Sam_NP B_NP for_IN 5_CD days_NNS ._SENT Total_JJ ,_, viable_JJ ,_, and_CC nonviable_JJ cells_NNS were_VBD counted_VBN three_CD times_NNS under_IN the_DT microscope_NN with_IN the_DT help_NN of_IN a_DT hemocytometer_NNS following_VBG staining_VBG by_IN trypan_JJ blue_NN ._SENT The_DT percentage_NN of_IN viable_JJ cells_NNS was_VBD calculated_VBN ._SENT The_DT cell_NN viability_NN was_VBD also_RB evaluated_VBN as_IN lactate_NN dehydrogenase_NN (_( LDH_NP )_) release_NN according_VBG to_TO the_DT manufacturer_NN 's_POS instructions_NNS (_( Roche_NP ,_, Milan_NP ,_, Italy_NP )_) ._SENT LDH_NN activity_NN in_IN milliunits_NNS per_IN milliliter_NN ,_, where_WRB 1_CD mU_NN is_VBZ the_DT amount_NN of_IN enzyme_NN required_VBN to_TO transform_VB 0.0167_CD nM_NN NAD_NN per_IN min_NP ,_, was_VBD determined_VBN ._SENT Effect_NN of_IN Sam_NP B_NP on_IN Vero_NP cell_NN growth_NN ._SENT |_SYM The_DT method_NN was_VBD modified_VBN from_IN that_DT previously_RB described_VBN ._SENT For_IN the_DT analysis_NN of_IN total_JJ cellular_JJ protein_NN synthesis_NN ,_, Vero_NP cells_NNS were_VBD preincubated_VBN with_IN leucine-free_JJ MEM_NP for_IN 1_CD day_NN and_CC then_RB cultured_VBN in_IN MEM_NP containing_VBG 2_CD %_NN fetal_JJ calf_NN serum_NN ._SENT The_DT cells_NNS (_( 5_CD x_SYM 103/well_NP )_) were_VBD incubated_VBN with_IN or_CC without_IN Sam_NP B_NP at_IN various_JJ concentrations_NNS for_IN 5_CD days_NNS ._SENT Then_RB ,_, for_IN detection_NN of_IN DNA_NP ,_, RNA_NP ,_, and_CC protein_NN synthesis_NN in_IN Vero_NP cells_NNS ,_, tritiated_VBN thymidine_NN ,_, tritiated_VBN uridine_NN ,_, or_CC tritiated_VBD leucine_NN was_VBD added_VBN into_IN each_DT well_RB (_( 1_CD muCi/well_NN ;_: NEN_NP )_) ,_, respectively_RB ._SENT After_IN a_DT 16-h_NP incubation_NN ,_, the_DT cells_NNS were_VBD harvested_VBN on_IN glass_NN fiber_NN filters_NNS by_IN an_DT automatic_JJ harvester_NN (_( Multimash_NP 2000_CD ;_: Dynatech_NP ,_, Billingshurst_NP ,_, United_NP Kingdom_NP )_) ._SENT Radioactivity_NN in_IN the_DT filters_NNS was_VBD measured_VBN by_IN scintillation_NN counting_NN ._SENT Extraction_NN of_IN total_JJ cellular_JJ DNA_NP and_CC RNA_NP ._SENT |_SYM Cellular_NP DNA_NP and_CC RNA_NP were_VBD extracted_VBN from_IN Vero_NP cells_NNS by_IN the_DT method_NN described_VBD previously_RB ._SENT Vero_NP cells_NNS (_( 5_CD x_SYM 106_CD )_) were_VBD infected_VBN with_IN HSV-1_NP at_IN an_DT MOI_NP of_IN 3_CD or_CC were_VBD not_RB infected_VBN in_IN the_DT presence_NN or_CC absence_NN of_IN Sam_NP B_NP (_( 25_CD muM_NN )_) and_CC harvested_VBN at_IN various_JJ times_NNS ._SENT For_IN DNA_NN extraction_NN ,_, the_DT cells_NNS were_VBD lysed_VBN with_IN 0.2_CD M_NP Tris-HCl_NP (_( pH_NN 8.5_CD )_) containing_VBG 100_CD mM_NP EDTA_NP ,_, 100_CD mM_NP NaCl_NP ,_, 0.5_CD %_NN NP-40_NP ,_, 1_CD %_NN sodium_NN dodecyl_NN sulfate_NN (_( SDS_NP )_) ,_, and_CC 100_CD mug_NN of_IN proteinase_NN K/ml_NP ._SENT To_TO extract_VB cellular_JJ RNA_NP ,_, Vero_NP cells_NNS were_VBD washed_VBN by_IN cold_JJ Tris-saline_NP (_( pH_NN 7.4_CD )_) and_CC then_RB suspended_VBN in_IN NDD_JJ buffer_NN (_( 1_CD %_NN NP-40_NP ,_, 0.5_CD %_NN sodium_NN deoxycholate_NN ,_, 1_CD %_NN dextran_NN sulfate_NN )_) ._SENT The_DT DNA_NP and_CC RNA_NP solutions_NNS were_VBD extracted_VBN with_IN phenol-chloroform_NN and_CC precipitated_VBD with_IN 100_CD %_NN cold_JJ ethanol_NN ,_, and_CC their_PP$ concentrations_NNS were_VBD determined_VBN by_IN measuring_VBG the_DT optical_JJ density_NN at_IN 260_CD nm_NN ._SENT Synthesis_NN of_IN first-strand_NN cDNA_NN ._SENT |_SYM The_DT method_NN followed_VBD procedures_NNS described_VBD previously_RB ._SENT Aliquots_NNS of_IN 1_CD mug_NN of_IN RNA_NP were_VBD reverse_RB transcribed_VBN with_IN the_DT Advantage_NP RT-for-PCR_NP kit_NN from_IN Clontech_NP according_VBG to_TO the_DT manufacturer_NN 's_POS instructions_NNS ._SENT The_DT reaction_NN mixture_NN was_VBD initially_RB incubated_VBN at_IN 42C_JJ for_IN 1_CD h_NN and_CC then_RB at_IN 94C_NN for_IN 5_CD min_NN to_TO terminate_VB the_DT reaction_NN ._SENT Diethyl_NP pyrocarbonate-treated_JJ H2O_NP (_( 80_CD mul_NN )_) was_VBD added_VBN to_TO the_DT tube_NN ,_, and_CC the_DT tube_NN was_VBD then_RB stored_VBN at_IN -20C_NN for_IN use_NN in_IN the_DT PCR_NP ._SENT PCR_NP ._SENT |_SYM The_DT method_NN has_VBZ been_VBN described_VBN elsewhere_RB ._SENT Briefly_RB ,_, 10_CD mul_NN of_IN cDNA_NN or_CC total_JJ cellular_JJ DNA_NN was_VBD mixed_VBN with_IN 0.75_CD muM_NN primers_NNS ,_, 4_CD U_NP of_IN Taq_NP polymerase_NN ,_, 10_CD mul_NN of_IN reaction_NN buffer_NN (_( 2_CD mM_NP Tris-HCl_NP [_SYM pH_NN 8.0_CD ]_SYM ,_, 0.01_CD mM_NP EDTA_NP ,_, 0.1_CD mM_NP dithiothreitol_NN ,_, 0.1_CD %_NN Triton_NP X-100_NP ,_, 5_CD %_NN glycerol_NN ,_, 1.5_CD mM_NP MgCl2_NP )_) ,_, and_CC 25_CD mul_NN of_IN water_NN in_IN a_DT total_JJ volume_NN of_IN 50_CD mul_NN ._SENT The_DT oligonucleotide_NN primer_NN pairs_NNS were_VBD as_RB follows_VBZ :_: for_IN gB_NN (_( amplification_NN fragment_NN ,_, 341_CD bp_NN )_) ,_, 5'-CTGGTCAGCTTTCGGTACGA-3_NP '_POS and_CC 3'-CGTTTGTCGACGTGCTGGAC-5_JJ '_'' ;_: for_IN HSV-1_NP DNA_NP polymerase_NN (_( 600_CD bp_NN )_) ,_, 5'-CGCACCATCTACGACGGCCAGC-3_NP '_POS and_CC 3'-CGCTTTCGTCTAGGCGAGCGCC-5_JJ '_'' ;_: for_IN ICP0_NP (_( 157_CD bp_NN )_) ,_, 5'-TTCGGTCTCCGCCTGAGAGT-3_NP '_POS and_CC 3'-AGCATACGCCGACCTCCCAG-5_JJ '_'' ;_: for_IN ICP4_NP (_( 670_CD bp_NN )_) ,_, 5'-CCCGCCGATGCTGCCCTAAAC-3_NP '_POS and_CC 3'-TTCGCCAGACACCTACTCAAG-5_JJ '_'' ;_: for_IN beta-actin_NN (_( 1,300_CD bp_NN )_) ,_, 5'-TTGAGACCTTCAACACCC-3_NP '_POS and_CC 3'-CTCTACTGAAGCTTTTCGACT_JJ ._SENT The_DT PCR_NP was_VBD done_VBN at_IN the_DT following_VBG settings_NNS of_IN the_DT air_NN thermocycler_NN :_: denaturing_VBG temperature_NN of_IN 94C_NN for_IN 1_CD min_NN ,_, annealing_VBG temperature_NN of_IN 53C_NN for_IN 1_CD min_NN ,_, and_CC elongation_NN temperatures_NNS of_IN 72C_NP for_IN 2_CD min_NN for_IN the_DT first_JJ 25_CD cycles_NNS and_CC then_RB 72C_JJ for_IN 10_CD min_NN ._SENT The_DT amplified_VBN products_NNS were_VBD quantitated_VBN with_IN laser_NN scanning_VBG densitometer_NN SLR-2D/1D_NNS (_( Biomed_NP Instruments_NPS Inc._NP ,_, Fullerton_NP ,_, Calif._NP )_) ._SENT Northern_JJ blot_NN analysis_NN ._SENT |_SYM The_DT analysis_NN was_VBD modified_VBN from_IN that_DT previously_RB described_VBN ._SENT The_DT HSV-1-infected_NP (_( MOI_NP ,_, 3_CD )_) Vero_NP cells_NNS (_( 5_CD x_SYM 106_CD )_) were_VBD cultured_VBN with_IN or_CC without_IN Sam_NP B_NP (_( 25_CD muM_NN )_) for_IN 6_CD h._NN A_DT 15-mug_JJ sample_NN of_IN total_JJ cellular_JJ RNA_NP was_VBD resolved_VBN on_IN a_DT 6.66_CD %_NN formaldehyde-agarose_NN gel_NN and_CC then_RB transferred_VBN to_TO a_DT nitrocellulose_NN filter_NN (_( Schleicher_NP &_CC Schuell_NP )_) with_IN 20x_NP SSC_NP (_( 1x_NP SSC_NP is_VBZ 0.15_CD M_NP NaCl_NP plus_CC 0.015_CD M_NP sodium_NN citrate_NN )_) ._SENT The_DT filter_NN was_VBD prehybridized_JJ at_IN 42C_JJ for_IN 4_CD h_NN (_( prehybridization_NN solution_NN of_IN 0.1_CD %_NN sodium_NN pyrophosphate_NN ,_, 0.25_CD mg_NN of_IN denatured_VBN salmon_NN sperm_NN DNA/ml_NP ,_, and_CC 50_CD %_NN deionized_JJ formamide_NN )_) ._SENT A_DT digoxigenin-dUTP_NN (_( Boehringer_NP GmbH_NP ,_, Mannheim_NP ,_, Germany)-labeled_NP DNA_NP polymerase_NN probe_NN prepared_VBN by_IN PCR_NP was_VBD added_VBN to_TO the_DT same_JJ solution_NN and_CC incubated_VBN at_IN 42C_JJ for_IN 12_CD h._NNS The_DT filter_NN was_VBD washed_VBN with_IN 0.1x_NP SSC_NP ,_, detected_VBN by_IN enzyme_NN immunoassay_NN using_VBG an_DT antibody_NN conjugated_VBN to_TO alkaline_JJ phosphatase_NN (_( Boehringer_NP GmbH_NP )_) ,_, and_CC visualized_VBD by_IN the_DT chemiluminescence_NN recorded_VBN on_IN X-ray_NN film_NN (_( Kodak_NP )_) ._SENT Western_JJ blot_NN analysis_NN ._SENT |_SYM The_DT experiment_NN followed_VBD procedures_NNS described_VBD previously_RB ._SENT The_DT 5_CD x_SYM 106_CD Vero_NP cells_NNS were_VBD infected_VBN with_IN HSV-1_NP at_IN an_DT MOI_NP of_IN 3_CD or_CC were_VBD not_RB infected_VBN in_IN the_DT presence_NN or_CC absence_NN of_IN Sam_NP B_NP (_( 25_CD muM_NN )_) for_IN 16_CD h._JJ Extracted_JJ cellular_JJ proteins_NNS (_( 20_CD mug_NN )_) were_VBD dissolved_VBN in_IN the_DT dissociation_NN buffer_NN (_( 2_CD %_NN SDS_NP ,_, 5_CD %_NN beta-mercaptoethanol_NN ,_, 0.05_CD M_NP Tris-HCl_NP ,_, 20_CD %_NN glycerol_NN ,_, pH_NN 7.6_CD )_) and_CC resolved_VBN by_IN SDS-10_NP %_NN polyacrylamide_NN gel_NN electrophoresis_NN (_( PAGE_NP )_) then_RB transferred_VBN to_TO nitrocellulose_NN filters_NNS ._SENT After_IN filters_NNS were_VBD blocked_VBN ,_, they_PP were_VBD incubated_VBN with_IN mouse_NN monoclonal_NN antibodies_NNS (_( Virusys_NP Corporation_NP ,_, East_NP Coast_NP Biologics_NP ,_, Inc._NP ,_, North_NP Berwick_NP ,_, Maine_NP )_) raised_VBD against_IN HSV-1_JJ gamma_NN proteins_NNS (_( gB_NP ,_, gC_NN ,_, gD_NNS ,_, gG_NN ,_, or_CC ICP5_NP )_) and_CC alpha_NN proteins_NNS (_( ICP0_NP or_CC ICP4_NP )_) ._SENT Specific_JJ reactive_JJ proteins_NNS were_VBD detected_VBN by_IN an_DT enhanced_JJ chemiluminescence_NN method_NN employing_VBG a_DT rabbit_NN anti-mouse_NN immunoglobulin_NN antibody_NN linked_VBN to_TO horseradish_NN peroxidase_NN (_( Santa_NP Cruz_NP Biotechnology_NP ,_, Inc._NP ,_, Santa_NP Cruz_NP ,_, Calif._NP )_) ._SENT Electrophoretic_JJ mobility_NN shift_NN assay_NN (_( EMSA_NP )_) ._SENT |_SYM Oligonucleotide_NP sequences_NNS 5'-GATCCCGTGCATGCTAATGATATTCTTTGGG-3_NP '_POS and_CC 3'-GGCACGTACGATTACTATAAGAAACCCCTAG-5_NP '_POS ,_, corresponding_VBG to_TO consensus_NN alphaTIF/C1/Oct-1_JJ site_NN (_( nucleotides_NNS -170_CD to_TO -143_CD )_) of_IN the_DT ICP0_NP gene_NN were_VBD used_VBN as_IN a_DT probe_NN ._SENT Nuclear_NP extracts_VBZ of_IN HSV-1-infected_NP Vero_NP cells_NNS were_VBD prepared_VBN 5_CD h_NN after_IN infecting_VBG cells_NNS at_IN an_DT MOI_NP of_IN 20_CD ._SENT Reaction_NN mixtures_NNS (_( 15_CD mul_NN )_) contained_VBN ,_, together_RB with_IN 3_CD mug_NN of_IN nuclear_JJ extracts_VBZ ,_, 5_CD x_SYM 104_CD dpm_NN of_IN 32P-end-labeled_JJ probe_NN ,_, 2_CD mug_NN of_IN poly(dI-dC)_NN ,_, 5_CD %_NN glycerol_NN ,_, 1_CD mM_NP EDTA_NP ,_, 100_CD mM_NP KCl_NP ,_, 5_CD mM_NP MgCl2_NP ,_, 1_CD mM_NP dithiothreitol_NN ,_, and_CC 10_CD mM_NP Tris-HCl_NP ,_, pH_NN 7.4_CD ._SENT After_IN incubation_NN for_IN 30_CD min_NN at_IN room_NN temperature_NN ,_, reaction_NN mixtures_NNS were_VBD applied_VBN to_TO 4_CD %_NN polyacrylamide_NN gels_NNS in_IN 0.5_CD %_NN Tris-borate-EDTA_NP buffer_NN ._SENT When_WRB the_DT effect_NN of_IN Sam_NP B_NP on_IN the_DT binding_NN of_IN the_DT alphaTIF/C1/OTF-1_JJ multiple-protein_NN complex_JJ to_TO the_DT probes_NNS was_VBD determined_VBN ,_, nuclear_JJ extracts_VBZ from_IN HSV-1-infected_NP Vero_NP cells_NNS were_VBD treated_VBN with_IN 25_CD muM_NN Sam_NP B_NP for_IN 5_CD min_NN prior_JJ to_TO the_DT addition_NN of_IN the_DT probes_NNS ._SENT Statistical_JJ analysis_NN ._SENT |_SYM Data_NP were_VBD presented_VBN as_IN means_NN +-_NN standard_NN deviations_NNS ,_, and_CC the_DT differences_NNS between_IN groups_NNS were_VBD assessed_VBN with_IN Student_NP 's_POS t_NN test_NN ._SENT Effects_NNS of_IN ethanolic_NN extracts_VBZ from_IN 10_CD Chinese_JJ herbs_NNS on_IN HSV-1_JJ replication_NN ._SENT |_SYM As_RB shown_VBN in_IN Fig._NN ,_, ethanolic_NN extracts_VBZ isolated_VBN from_IN 10_CD Chinese_JJ herbs_NNS were_VBD evaluated_VBN for_IN their_PP$ activities_NNS in_IN inhibiting_VBG HSV-1_JJ plaque_NN formation_NN in_IN Vero_NP cells_NNS ._SENT HSV-1_JJ replication_NN was_VBD not_RB affected_VBN by_IN DMSO_NP treatment_NN ._SENT Acyclovir_NN blocked_VBD HSV-1_JJ plaque_NN formation_NN in_IN Vero_NP cells_NNS ._SENT While_IN ethanolic_NN extracts_VBZ from_IN Ventilago_NP leiocarpa_NP ,_, Ecdysanthera_NP rosea_NP ,_, Ecdysanthera_NP utilis_NP ,_, Hippobroma_NP longiflora_NP ,_, Ardrisia_NP brevicaulis_NP ,_, Selaginella_NP delicatula_NP ,_, Ardrisia_NP japonica_NN ,_, Ardrisia_NP violacea_NP ,_, and_CC Andendron_NP benthamianum_NN had_VBD little_JJ effect_NN on_IN HSV-1_JJ replication_NN ,_, 100_CD mug_NN of_IN L._NP sinense_NN ethanolic_NN extracts/ml_NN significantly_RB suppressed_VBD HSV-1_JJ replication_NN ._SENT The_DT inhibitory_JJ action_NN of_IN L._NP sinense_NN ethanolic_NN extracts_VBZ on_IN HSV-1_JJ replication_NN was_VBD concentration_NN dependent_JJ ._SENT The_DT 50_CD %_NN inhibitory_JJ concentration_NN (_( IC50_NP )_) of_IN L._NP sinense_NN ethanolic_NN extracts_VBZ for_IN HSV-1_JJ replication_NN was_VBD 25.0_CD +-_NN 8.7_CD mug/ml_NN ._SENT Sam_NP B_NP identified_VBD from_IN L._NP sinense_NN inhibits_VBZ HSV-1_JJ replication_NN ._SENT |_SYM To_TO extract_VB pure_JJ active_JJ compounds_NNS from_IN L._NP sinense_NN ,_, we_PP used_VBD the_DT complete_JJ isolation_NN process_NN in_IN each_DT chromatographic_JJ cycle_NN and_CC finally_RB HPLC_NP ._SENT The_DT compound_NN with_IN the_DT strongest_JJS activity_NN was_VBD a_DT brown_JJ amorphous_JJ powder_NN ._SENT Nuclear_JJ magnetic_JJ resonance_NN (_( NMR_NP )_) and_CC mass_JJ spectrum_NN analyses_NNS indicated_VBD the_DT structure_NN shown_VBN in_IN Fig._NN ._SENT The_DT chemical_NN name_NN of_IN this_DT bioactive_JJ component_NN is_VBZ galloyl-epigallocatechin_NN (_( [_SYM 4beta->8_JJ ,_, 2'->3"-O]-galloyl-epigallocatechin_NP ;_: C44H31O22_NP ;_: molecular_JJ weight_NN ,_, 911_CD )_) ._SENT Both_DT mass_NN and_CC NMR_NP spectrum_NN data_NNS for_IN the_DT compound_NN were_VBD compatible_JJ with_IN those_DT previously_RB reported_VBN for_IN Sam_NP B_NP by_IN Nonaka_NP et_FW al._FW ._SENT The_DT common_JJ name_NN given_VBN to_TO this_DT component_NN at_IN that_DT time_NN was_VBD Sam_NP B._NP The_DT purity_NN of_IN Sam_NP B_NP was_VBD assessed_VBN by_IN an_DT HPLC_NP purity_NN program_NN (_( column_NN 5C18-MS_NNS )_) ._SENT The_DT column_NN was_VBD eluted_VBN with_IN a_DT 35:65_CD (_( vol/vol_NN )_) mixture_NN of_IN methanol_NN and_CC 0.1_CD %_NN H3PO4_NP and_CC analyzed_VBD by_IN a_DT UV_NP detector_NN at_IN 254_CD nm_NN ._SENT Sam_NP B_NP appeared_VBD as_IN a_DT single_JJ peak_NN at_IN a_DT 3.973-min_JJ retention_NN time_NN ,_, and_CC its_PP$ purity_NN was_VBD 99.0_CD %_NN ._SENT As_IN shown_VBN in_IN Fig._NN ,_, Sam_NP B_NP blocked_VBD virus_NN amplification_NN ,_, and_CC thus_RB its_PP$ presence_NN resulted_VBD in_IN the_DT formation_NN of_IN a_DT cytopathic_JJ effect_NN significant_JJ lower_JJR than_IN that_IN in_IN control_NN infections_NNS ._SENT The_DT results_NNS of_IN plaque_NN reduction_NN assay_NN indicated_VBD that_IN the_DT inhibitory_JJ effect_NN of_IN Sam_NP B_NP on_IN HSV-1_NP replication_NN was_VBD concentration_NN dependent_JJ ._SENT At_IN 6.25_CD muM_NN ,_, Sam_NP B_NP suppressed_VBD HSV-1_JJ replication_NN by_IN 24.6_CD %_NN +-_NN 4.2_CD %_NN ._SENT The_DT corresponding_JJ degrees_NNS of_IN inhibition_NN for_IN 12.5_CD ,_, 25_CD ,_, 50_CD ,_, and_CC 100_CD muM_NN were_VBD 58.3_CD +-_NN 3.0_CD ,_, 88.5_CD +-_NN 7.3_CD ,_, 100_CD +-_NN 5.2_CD ,_, and_CC 100_CD %_NN +-_NN 2.2_CD %_NN ,_, respectively_RB ,_, with_IN an_DT IC50_NP value_NN of_IN 11.4_CD +-_NN 0.9_CD muM_NN ._SENT Effects_NNS of_IN Sam_NP B_NP on_IN viability_NN and_CC growth_NN of_IN Vero_NP cells_NNS ._SENT |_SYM To_TO delineate_VB whether_IN the_DT suppressive_JJ effect_NN of_IN Sam_NP B_NP on_IN HSV-1_NP replication_NN was_VBD related_VBN to_TO cytotoxicity_NN ,_, we_PP examined_VBD the_DT viability_NN of_IN Vero_NP cells_NNS after_IN treatment_NN with_IN Sam_NP B_NP for_IN 5_CD days_NNS ._SENT DMSO_NP did_VBD not_RB affect_VB cell_NN viability_NN ._SENT Compared_VBN with_IN that_IN of_IN control_NN groups_NNS ,_, the_DT viability_NN of_IN Vero_NP cells_NNS treated_VBN with_IN 25_CD ,_, 50_CD ,_, and_CC 100_CD muM_NN Sam_NP B_NP was_VBD not_RB significantly_RB decreased_VBN ._SENT Moreover_RB ,_, an_DT evaluation_NN of_IN the_DT cytotoxic_JJ effect_NN of_IN Sam_NP B_NP on_IN Vero_NP cells_NNS in_IN terms_NNS of_IN LDH_NP release_NN indicated_VBD that_IN LDH_NP release_NN from_IN Vero_NP cells_NNS in_IN the_DT presence_NN of_IN 100_CD muM_NN Sam_NP B_NP for_IN 5_CD days_NNS was_VBD not_RB significantly_RB different_JJ from_IN that_DT in_IN the_DT absence_NN of_IN Sam_NP B_NP (_( 3.23_CD +-_NN 2.2_CD versus_CC 4.05_CD +-_NN 1.7_CD mU/ml_NN )_) ._SENT Results_NNS indicated_VBD that_IN ,_, even_RB at_IN 200_CD muM_NN ,_, Sam_NP B_NP had_VBD no_DT direct_JJ cytotoxicity_NN on_IN Vero_NP cells_NNS (_( data_NNS not_RB shown_VBN )_) ._SENT The_DT therapeutic_JJ index_NN (_( 50_CD %_NN effective_JJ concentration/IC50_NN )_) for_IN Sam_NP B_NP is_VBZ higher_JJR than_IN 18_CD ._SENT Additionally_RB ,_, effects_NNS of_IN Sam_NP B_NP on_IN Vero_NP cell_NN growth_NN were_VBD determined_VBN by_IN tritiated_VBN thymidine_NN ,_, tritiated_VBN uridine_NN ,_, and_CC tritiated_VBD leucine_NN uptake_NN methods_NNS ._SENT As_IN shown_VBN in_IN Fig._NN ,_, Sam_NP B_NP did_VBD not_RB affect_VB DNA_NP ,_, RNA_NP ,_, and_CC protein_NN synthesis_NN in_IN Vero_NP cells_NNS ._SENT These_DT results_NNS demonstrated_VBD that_IN inhibitory_JJ mechanisms_NNS of_IN Sam_NP B_NP on_IN HSV-1_NP replication_NN were_VBD not_RB due_JJ to_TO cytotoxicity_NN and_CC did_VBD not_RB arrest_VB Vero_NP cell_NN growth_NN ._SENT Effect_NN of_IN Sam_NP B_NP on_IN HSV-1_NP adsorption_NN ._SENT |_SYM To_TO further_RBR elucidate_VB whether_IN Sam_NP B_NP inhibition_NN of_IN HSV-1_NP replication_NN was_VBD related_VBN to_TO blocking_VBG viral_JJ adsorption_NN ,_, we_PP examined_VBD the_DT effect_NN of_IN its_PP$ addition_NN at_IN various_JJ times_NNS ._SENT Cell_NN supernatants_NNS were_VBD collected_VBN at_IN 0_CD ,_, 2_CD ,_, 4_CD ,_, 6_CD ,_, 8_CD ,_, 16_CD ,_, 24_CD ,_, and_CC 36_CD h_NN p.i._NN ,_, and_CC HSV-1_NP titers_NNS were_VBD determined_VBN by_IN a_DT plaque_NN forming_VBG assay_NN ._SENT As_IN shown_VBN in_IN Fig._NN ,_, the_DT virus_NN titers_NNS in_IN cell_NN supernatants_NNS gradually_RB increased_VBN at_IN 8_CD h_NN p.i._NN and_CC the_DT highest_JJS titer_NN was_VBD obtained_VBN at_IN 24_CD h_NN p.i._NP DMSO_NP did_VBD not_RB affect_VB HSV-1_JJ amplification_NN ._SENT By_IN contrast_NN ,_, whether_IN 25_CD muM_NN Sam_NP B_NP was_VBD added_VBN at_IN the_DT same_JJ time_NN as_IN HSV-1_NP or_CC after_IN HSV-1_JJ adsorption_NN for_IN 1_CD h_NN ,_, the_DT virus_NN titers_NNS in_IN cell_NN supernatants_NNS were_VBD decreased_VBN ._SENT The_DT same_JJ results_NNS were_VBD obtained_VBN in_IN acyclovir-treated_JJ cells_NNS ._SENT In_IN addition_NN ,_, the_DT pretreatment_NN of_IN Vero_NP cells_NNS with_IN 25_CD muM_NN Sam_NP B_NP for_IN 2.5_CD h_NN before_IN infection_NN still_RB inhibited_VBD virus_NN yield_NN ._SENT These_DT results_NNS demonstrated_VBD that_IN Sam_NP B_NP did_VBD not_RB affect_VB HSV-1_JJ adsorption_NN to_TO host_NN cells_NNS ._SENT Time_NN course_NN analysis_NN of_IN the_DT effect_NN of_IN Sam_NP B_NP on_IN HSV-1_NP replication_NN ._SENT |_SYM Time_NP course_NN experiments_NNS were_VBD performed_VBN to_TO determine_VB at_IN what_WP point_NN in_IN the_DT replication_NN process_NN Sam_NP B_NP inhibited_VBD HSV-1_JJ replication_NN ._SENT Sam_NP B_NP (_( 25_CD muM_NN )_) was_VBD added_VBN at_IN the_DT same_JJ time_NN as_IN HSV-1_NP (_( 0_CD h_NN p.i._NN )_) or_CC at_IN 2_CD ,_, 4_CD ,_, 6_CD ,_, 8_CD ,_, 12_CD ,_, 16_CD ,_, and_CC 24_CD h_NN p.i._NN The_DT cell_NN supernatants_NNS were_VBD collected_VBN at_IN 25_CD h_NN p.i._NN ,_, and_CC a_DT plaque_NN forming_VBG assay_NN was_VBD performed_VBN ._SENT The_DT results_NNS indicated_VBD that_DT addition_NN of_IN Sam_NP B_NP between_IN 0_CD and_CC 8_CD h_NN suppressed_VBN HSV-1_NP replication_NN ._SENT Addition_NN of_IN Sam_NP B_NP at_IN 12_CD to_TO 24_CD h_NN p.i._NN had_VBD only_RB minimal_JJ inhibitory_JJ effects_NNS on_IN HSV-1_JJ replication_NN ._SENT The_DT fact_NN that_IN Sam_NP B_NP was_VBD inhibitory_JJ when_WRB added_VBN between_IN 0_CD and_CC 8_CD hr_NN p.i._NN suggested_VBD that_IN the_DT suppressive_JJ effects_NNS of_IN Sam_NP B_NP might_MD be_VB related_VBN to_TO the_DT blocking_VBG of_IN biochemical_JJ events_NNS or_CC gene_NN expression_NN such_JJ as_IN that_DT of_IN the_DT alpha_NN ,_, beta_NN ,_, and_CC gamma_NN genes_NNS ,_, which_WDT are_VBP necessary_JJ for_IN HSV-1_JJ replication_NN during_IN this_DT time_NN frame_NN ._SENT Effects_NNS of_IN Sam_NP B_NP on_IN HSV-1_NP gamma_NN gene_NN expression_NN in_IN Vero_NP cells_NNS ._SENT |_SYM After_IN adsorption_NN ,_, HSV-1_NP expresses_VBZ gamma_NN genes_NNS about_RB at_IN 6_CD to_TO 8_CD h_NN p.i._NN or_CC even_RB earlier_RBR ._SENT The_DT genes_NNS are_VBP needed_VBN for_IN packaging_VBG viral_JJ particles_NNS ._SENT We_PP analyzed_VBD whether_IN Sam_NP B_NP suppression_NN of_IN HSV-1_NP replication_NN was_VBD related_VBN to_TO blocking_VBG the_DT synthesis_NN of_IN gamma_NN proteins_NNS in_IN Vero_NP cells_NNS ._SENT After_IN cells_NNS were_VBD treated_VBN with_IN 25_CD muM_NN Sam_NP B_NP for_IN 16_CD h_NN ,_, the_DT total_JJ cellular_JJ proteins_NNS were_VBD extracted_VBN and_CC the_DT expression_NN of_IN viral_JJ gamma_NN proteins_NNS including_VBG gB_NN ,_, gC_NN ,_, gD_NNS ,_, gG_NN ,_, and_CC ICP5_NP in_IN Vero_NP cells_NNS was_VBD determined_VBN by_IN Western_JJ blot_NN analysis_NN ._SENT As_IN shown_VBN in_IN Fig._NN ,_, while_IN uninfected_JJ cells_NNS expressed_VBD few_JJ of_IN these_DT gamma_NN proteins_VBZ (_( lane_NN 1_CD )_) ,_, the_DT gB_NN (_( 116_CD kDa_NNS )_) ,_, gC_NN (_( 78_CD kDa_NNS )_) ,_, gD_NNS (_( 55_CD kDa_NNS )_) ,_, gG_NN (_( 45_CD kDa_NNS )_) ,_, and_CC ICP5_NP (_( 155_CD kDa_NN )_) proteins_NNS were_VBD detectable_JJ in_IN HSV-1-infected_NP Vero_NP cells_NNS (_( lane_NN 2_CD )_) ._SENT However_RB ,_, Sam_NP B_NP suppressed_VBD the_DT expression_NN of_IN these_DT gamma_NN proteins_NNS in_IN Vero_NP cells_NNS (_( lane_NN 3_CD )_) ._SENT When_WRB Sam_NP B_NP was_VBD added_VBN at_IN 12_CD h_NN to_TO 16_CD h_NN p.i._NN ,_, the_DT inhibitory_JJ action_NN of_IN Sam_NP B_NP was_VBD interrupted_VBN and_CC the_DT expression_NN of_IN gamma_NN proteins_NNS in_IN Vero_NP cells_NNS was_VBD restored_VBN (_( lane_NN 4_CD )_) ._SENT A_DT graphical_JJ representation_NN of_IN the_DT ratio_NN of_IN gamma_NN proteins_NNS to_TO beta-actin_NN in_IN Vero_NP cells_NNS indicated_VBD that_IN little_JJ signal_NN was_VBD expressed_VBN in_IN the_DT cells_NNS treated_VBN with_IN HSV-1_NP and_CC Sam_NP B_NP at_IN the_DT same_JJ time_NN ._SENT Because_IN production_NN of_IN gB_NN proteins_NNS in_IN Vero_NP cells_NNS was_VBD attenuated_VBN ,_, we_PP determined_VBD whether_IN gB_NN mRNA_NN expression_NN in_IN the_DT cells_NNS was_VBD affected_VBN by_IN Sam_NP B._NP At_IN 16_CD h_NN p.i._NN ,_, the_DT total_JJ cellular_JJ RNA_NP was_VBD collected_VBN from_IN Vero_NP cells_NNS in_IN the_DT presence_NN or_CC absence_NN of_IN Sam_NP B_NP (_( 25_CD muM_NN )_) and_CC was_VBD available_JJ for_IN reverse_JJ transcription-PCR_NN (_( RT-PCR_NP )_) ._SENT Initially_RB ,_, we_PP examined_VBD the_DT dose-response_NN relationship_NN of_IN the_DT PCR_NP amplification_NN of_IN cDNA_NN (_( data_NNS not_RB shown_VBN )_) ._SENT The_DT exponential_JJ phase_NN of_IN amplification_NN was_VBD determined_VBN by_IN performing_VBG 20_CD ,_, 25_CD ,_, and_CC 30_CD cycles_NNS ._SENT We_PP found_VBD that_IN 25_CD cycles_NNS of_IN PCR_NP were_VBD optimal_JJ for_IN the_DT virion_NN and_CC beta-actin_NN mRNAs_NNS ._SENT As_IN shown_VBN in_IN Fig._NN ,_, neither_CC DMSO_NP (_( lanes_NNS 1_CD and_CC 2_CD )_) nor_CC Sam_NP B_NP (_( lanes_NNS 3_CD and_CC 4_LS )_) affected_VBN the_DT levels_NNS of_IN beta-actin_NN mRNA_NN in_IN Vero_NP cells_NNS ._SENT While_IN little_JJ expression_NN of_IN gB_NN mRNA_NN was_VBD detectable_JJ in_IN uninfected_JJ Vero_NP cells_NNS (_( lane_NN 1_CD )_) ,_, the_DT levels_NNS of_IN gB_NN mRNA_NN were_VBD significantly_RB increased_VBN in_IN HSV-1-infected_JJ cells_NNS (_( lane_NN 2_CD )_) ._SENT By_IN contrast_NN ,_, the_DT level_NN of_IN RT-PCR_NP products_NNS for_IN gB_NN mRNA_NN amplified_VBN from_IN HSV-1-infected_NP Vero_NP cells_NNS was_VBD decreased_VBN by_IN Sam_NP B_NP (_( lane_NN 3_CD )_) ._SENT Laser_NN densitometry_NN analysis_NN demonstrated_VBD that_IN the_DT ratio_NN of_IN gB_NN to_TO beta-actin_NN mRNAs_NNS was_VBD significantly_RB decreased_VBN by_IN Sam_NP B._NP The_DT inhibition_NN of_IN gB_NN mRNA_NN expression_NN due_JJ to_TO Sam_NP B_NP activity_NN was_VBD blocked_VBN when_WRB Sam_NP B_NP was_VBD added_VBN in_IN Vero_NP cells_NNS between_IN 12_CD and_CC 16_CD h_NN p.i._NN (_( lane_NN 4_CD )_) ._SENT These_DT results_NNS suggested_VBD that_IN the_DT decrease_NN of_IN gB_NN proteins_NNS caused_VBN by_IN Sam_NP B_NP was_VBD the_DT result_NN of_IN a_DT deficiency_NN of_IN gB_NN mRNA_NN expression_NN in_IN Vero_NP cells_NNS ._SENT Effect_NN of_IN Sam_NP B_NP on_IN HSV-1_NP DNA_NP synthesis_NN ._SENT |_SYM Because_IN HSV-1_JJ gamma2_JJ genes_NNS such_JJ as_IN the_DT gC_NN gene_NN are_VBP dependent_JJ on_IN viral_JJ DNA_NN synthesis_NN for_IN expression_NN and_CC because_IN DNA_NN synthesis_NN plays_VBZ important_JJ roles_NNS in_IN HSV-1_JJ replication_NN ,_, we_PP further_VBP defined_VBN whether_IN Sam_NP B_NP has_VBZ any_DT effect_NN on_IN HSV-1_NP DNA_NP synthesis_NN in_IN Vero_NP cells_NNS ._SENT After_IN HSV-1_JJ adsorption_NN ,_, the_DT cellular_JJ DNA_NN was_VBD harvested_VBN at_IN 2_CD ,_, 4_CD ,_, 8_CD ,_, and_CC 16_CD h_NN p.i._NN and_CC viral_JJ DNA_NN was_VBD analyzed_VBN by_IN PCR_NP ._SENT As_IN shown_VBN in_IN Fig._NN ,_, although_IN HSV-1_NP DNA_NP could_MD not_RB be_VB detected_VBN in_IN uninfected_JJ Vero_NP cells_NNS (_( lane_NN 1_CD )_) ,_, HSV-1_NP DNA_NP synthesis_NN was_VBD increased_VBN in_IN HSV-1-infected_JJ cells_NNS (_( lanes_NNS 2_CD to_TO 5_CD )_) ._SENT Graphical_JJ representation_NN of_IN the_DT ratio_NN of_IN HSV-1_NP DNA_NP to_TO beta-actin_NP DNA_NP showed_VBD that_IN increasing_VBG the_DT signal_NN in_IN HSV-1-infected_JJ cells_NNS corresponded_VBN to_TO increasing_VBG the_DT p.i._JJ time_NN ._SENT By_IN contrast_NN ,_, 25_CD muM_NN Sam_NP B_NP suppressed_VBD viral_JJ DNA_NN synthesis_NN in_IN Vero_NP cells_NNS (_( Fig._NN ,_, lanes_NNS 1_CD to_TO 4_CD )_) ._SENT Additionally_RB ,_, HSV-1_NP DNA_NP synthesis_NN in_IN Vero_NP cells_NNS was_VBD restored_VBN when_WRB Sam_NP B_NP was_VBD added_VBN to_TO cells_NNS at_IN 12_CD h_NN to_TO 16_CD h_NN p.i._NN (_( lane_NN 5_CD )_) ._SENT These_DT results_NNS suggested_VBD that_IN the_DT blocking_VBG of_IN gC_NN protein_NN expression_NN and_CC HSV-1_JJ replication_NN by_IN Sam_NP B_NP was_VBD related_VBN to_TO impairment_NN of_IN HSV-1_NP DNA_NP synthesis_NN in_IN Vero_NP cells_NNS ._SENT DNA_NP polymerase_NN mRNA_NN expression_NN in_IN Sam_NP B-treated_NP Vero_NP cells_NNS detected_VBD by_IN Northern_JJ blot_NN analysis_NN ._SENT |_SYM The_DT appearance_NN of_IN HSV-1_JJ beta_JJ gene_NN products_NNS such_JJ as_IN DNA_NP polymerase_NN signals_VBZ the_DT onset_NN of_IN viral_JJ DNA_NN synthesis_NN ._SENT To_TO elucidate_VB whether_IN Sam_NP B-suppressed_NP HSV-1_NP DNA_NP synthesis_NN was_VBD related_VBN to_TO DNA_NP polymerase_NN gene_NN expression_NN ,_, the_DT cells_NNS were_VBD infected_VBN with_IN HSV-1_NP or_CC were_VBD not_RB infected_VBN in_IN the_DT presence_NN or_CC absence_NN of_IN Sam_NP B_NP (_( 25_CD muM_NN )_) for_IN 6_CD h_NN and_CC then_RB DNA_NP polymerase_NN mRNA_NN was_VBD determined_VBN by_IN Northern_JJ blot_NN analysis_NN ._SENT As_IN shown_VBN in_IN Fig._NN ,_, 3.8_CD kb_NN of_IN DNA_NP polymerase_NN mRNA_NN was_VBD expressed_VBN in_IN HSV-1-infected_NP Vero_NP cells_NNS (_( lane_NN 4_CD )_) but_CC was_VBD not_RB expressed_VBN in_IN uninfected_JJ cells_NNS (_( lane_NN 2_CD )_) ._SENT DMSO_NP did_VBD not_RB affect_VB DNA_NP polymerase_NN mRNA_NN expression_NN in_IN Vero_NP cells_NNS (_( lane_NN 1_CD )_) ._SENT The_DT level_NN of_IN DNA_NP polymerase_NN mRNA_NN was_VBD impeded_VBN by_IN Sam_NP B_NP treatment_NN (_( lane_NN 3_CD )_) ._SENT However_RB ,_, neither_CC DMSO_NP nor_CC Sam_NP B_NP affected_JJ beta-actin_NN mRNA_NN expression_NN in_IN Vero_NP cells_NNS ._SENT The_DT ratio_NN of_IN the_DT absorbance_NN value_NN for_IN DNA_NP polymerase_NN mRNA_NN to_TO that_DT for_IN the_DT beta-actin_NN mRNA_NN signal_NN was_VBD calculated_VBN ._SENT Results_NNS indicated_VBD that_IN Sam_NP B_NP significantly_RB attenuated_VBN the_DT ratio_NN of_IN HSV-1_NP DNA_NP polymerase_NN mRNA_NN to_TO beta-actin_NN mRNA_NN ._SENT The_DT data_NNS demonstrated_VBD that_IN Sam_NP B_NP blockage_NN of_IN HSV-1_NP DNA_NP synthesis_NN was_VBD related_VBN to_TO a_DT deficiency_NN of_IN DNA_NN polymerase_NN ._SENT Effects_NNS of_IN Sam_NP B_NP on_IN HSV-1_NP alpha_NN gene_NN expression_NN in_IN Vero_NP cells_NNS ._SENT |_SYM As_RB we_PP know_VBP ,_, beta_JJ genes_NNS of_IN HSV-1_NP are_VBP not_RB expressed_VBN in_IN the_DT absence_NN of_IN competent_JJ alpha_NN proteins_NNS such_JJ as_IN ICP0_NP and_CC ICP4_NP ._SENT To_TO confirm_VB that_IN Sam_NP B_NP inhibition_NN of_IN DNA_NP polymerase_NN mRNA_NN was_VBD related_VBN to_TO alpha_NN gene_NN expression_NN ,_, Vero_NP cells_NNS were_VBD infected_VBN with_IN HSV-1_NP or_CC were_VBD not_RB infected_VBN in_IN the_DT presence_NN or_CC absence_NN of_IN Sam_NP B._NP The_DT total_JJ cellular_JJ proteins_NNS was_VBD extracted_VBN at_IN 4_CD h_NN p.i._NN ,_, and_CC ICP0_NP and_CC ICP4_NP proteins_NNS were_VBD determined_VBN by_IN Western_JJ blot_NN analysis_NN ._SENT As_IN shown_VBN in_IN Fig._NN ,_, while_IN uninfected_JJ cells_NNS expressed_VBD few_JJ virus_NN ICP0_NP and_CC ICP4_NP proteins_NNS (_( lane_NN 1_CD )_) ,_, both_CC 110-kDa_NP ICP0_NP and_CC 175-kDa_NP ICP4_NP were_VBD synthesized_VBN in_IN HSV-1-infected_NP Vero_NP cells_NNS (_( lane_NN 4_CD )_) ._SENT DMSO_NP did_VBD not_RB affect_VB the_DT expression_NN of_IN either_DT protein_NN in_IN Vero_NP cells_NNS (_( lane_NN 2_CD )_) ._SENT However_RB ,_, Sam_NP B_NP decreased_VBD levels_NNS of_IN ICP0_NP and_CC ICP4_NP proteins_NNS in_IN HSV-1-infected_NP Vero_NP cells_NNS (_( lane_NN 3_CD )_) ._SENT Graphical_JJ representation_NN of_IN the_DT ratio_NN of_IN ICP0_NP or_CC ICP4_NP to_TO beta-actin_NN proteins_NNS in_IN Vero_NP cells_NNS indicated_VBD that_IN little_JJ signal_NN from_IN infected_JJ Vero_NP cells_NNS treated_VBN with_IN Sam_NP B_NP was_VBD detectable_JJ ._SENT Furthermore_RB ,_, RT-PCR_NP analysis_NN was_VBD applied_VBN to_TO determine_VB whether_IN decreasing_VBG ICP0_NP and_CC ICP4_NP mRNA_NP expression_NN caused_VBD the_DT impairment_NN of_IN protein_NN production_NN in_IN Sam_NP B-treated_NP cells_NNS ._SENT As_IN shown_VBN in_IN Fig._NN ,_, while_IN ICP0_NP and_CC ICP4_NP mRNAs_NNS were_VBD expressed_VBN in_IN HSV-1-infected_NP Vero_NP cells_NNS (_( lanes_NNS 2_CD and_CC 4_CD )_) ,_, Sam_NP B_NP decreased_VBD the_DT levels_NNS of_IN ICP0_NP and_CC ICP4_NP mRNAs_NNS in_IN the_DT cells_NNS (_( lane_NN 3_CD )_) ._SENT A_DT novel_JJ virus-induced_JJ protein-DNA_NN complex_NN reduced_VBN by_IN Sam_NP B._NP |_SYM The_DT formation_NN of_IN alphaTIF/C1/Oct-1/GARAT_NN multiprotein_NN complexes_NNS is_VBZ responsible_JJ for_IN induction_NN of_IN alpha_NN genes_NNS ._SENT To_TO determine_VB whether_IN Sam_NP B_NP suppression_NN of_IN ICP0_NP and_CC ICP4_NP transcripts_NNS was_VBD related_VBN to_TO this_DT initial_JJ transcriptional_JJ trans_NNS activation_NN event_NN ,_, the_DT radiolabeled_JJ DNA_NN fragment_NN containing_VBG GARAT_NP was_VBD incubated_VBN with_IN Sam_NP B-treated_JJ nuclear_JJ extracts_VBZ from_IN HSV-1-infected_JJ cells_NNS ._SENT As_IN shown_VBN in_IN Fig._NN ,_, with_IN extracts_VBZ from_IN infected_JJ cells_NNS ,_, a_DT novel_JJ virus-induced_JJ protein-DNA_NN complex_NN (_( IEC_NP )_) was_VBD detected_VBN (_( lanes_NNS 1_CD and_CC 4_CD )_) ._SENT While_IN DMSO_NP did_VBD not_RB influence_VB protein-DNA_NN complex_JJ formation_NN (_( lane_NN 1_CD )_) ,_, a_DT 50-fold_NN excess_NN of_IN unlabeled_JJ probe_NN blocked_VBD the_DT formation_NN of_IN these_DT complexes_NNS (_( lane_NN 5_CD )_) ._SENT The_DT level_NN of_IN IEC_NP was_VBD reduced_VBN by_IN Sam_NP B_NP treatment_NN (_( lane_NN 2_CD )_) ._SENT These_DT results_NNS suggest_VBP that_IN the_DT reduction_NN by_IN Sam_NP B_NP of_IN ICP0_NP and_CC ICP4_NP mRNAs_NNS might_MD be_VB related_VBN to_TO an_DT interruption_NN in_IN the_DT formation_NN of_IN alphaTIF/C1/Oct-1/GARAT_NN multiprotein_NN complexes_NNS ._SENT FIG._NN 1_CD ._SENT |_SYM Effects_NN of_IN ethanolic_NN extracts_VBZ from_IN 10_CD Chinese_JJ herbs_NNS on_IN HSV-1_JJ replication_NN in_IN Vero_NP cells_NNS determined_VBN by_IN plaque_NN reduction_NN assay_NN ._SENT Effects_NNS of_IN ethanolic_NN extracts_VBZ from_IN 10_CD Chinese_JJ herbs_NNS on_IN HSV-1_JJ replication_NN in_IN Vero_NP cells_NNS determined_VBN by_IN plaque_NN reduction_NN assay_NN ._SENT Vero_NP cells_NNS (_( 3.5_CD x_SYM 105/dish_JJ )_) were_VBD incubated_VBN with_IN 100_CD PFU_NP of_IN HSV-1_NP and_CC 10_CD muM_NN acyclovir_NN ,_, 100_CD mug_NN of_IN each_DT extract/ml_NN (_( A_NP )_) ,_, or_CC the_DT indicated_JJ concentrations_NNS of_IN L._NP sinense_NN extracts_VBZ (_( B_NP )_) ._SENT After_IN adsorption_NN for_IN 1_CD h_NN ,_, 1_CD %_NN methylcellulose_NN was_VBD added_VBN to_TO each_DT well_NN ._SENT On_IN the_DT fifth_JJ day_NN p.i._NN ,_, the_DT virus_NN plaques_NNS formed_VBN in_IN Vero_NP cells_NNS were_VBD counted_VBN by_IN crystal_NN violet_NN staining_VBG ._SENT Each_DT bar_NN represents_VBZ the_DT mean_NN of_IN three_CD independent_JJ experiments_NNS ._SENT VL_NP ,_, Ventilago_NP leiocarpa_NP ,_, ER_NP ,_, Ecdysanthera_NP rosea_NP ,_, EU_NP ,_, Ecdysanthera_NP utilis_NP ,_, HL_NP ,_, Hippobroma_NP longiflora_NP ,_, AB_NP ,_, Ardrisia_NP brevicaulis_NP ,_, SD_NP ,_, Selaginella_NP delicatula_NP ,_, LS_NP ,_, L._NP sinense_NN ,_, AJ_NP ,_, Ardrisia_NP japonica_NN ,_, AV_NP ,_, Ardrisia_NP violacea_NP ,_, AE_NP ,_, Andendron_NP benthamianum_NN ._SENT FIG._NN 2_CD ._SENT |_SYM The_DT structure_NN of_IN Sam_NP B_NP purified_VBD from_IN L._NP sinense_NN The_DT structure_NN of_IN Sam_NP B_NP purified_VBD from_IN L._NP sinense_NN ._SENT FIG._NN 3_CD ._SENT |_SYM Cytopathic_JJ effect_NN of_IN HSV-1_NP on_IN Vero_NP cells_NNS treated_VBN with_IN or_CC without_IN Sam_NP B._NP Cytopathic_NP effect_NN of_IN HSV-1_NP on_IN Vero_NP cells_NNS treated_VBN with_IN or_CC without_IN Sam_NP B._NP HSV-1-infected_NP (_( MOI_NP ,_, 3_CD )_) and_CC uninfected_JJ Vero_NP cells_NNS were_VBD treated_VBN with_IN or_CC without_IN Sam_NP B_NP (_( 25_CD muM_NN )_) ._SENT At_IN 22_CD h_NN p.i._NN ,_, cells_NNS were_VBD examined_VBN by_IN microscopy_NN (_( magnification_NN ,_, x180_NP )_) ._SENT Bar_NP ,_, 50_CD mum_NN ._SENT FIG._NN 4_CD ._SENT |_SYM Effects_NN of_IN Sam_NP B_NP on_IN HSV-1_NP replication_NN and_CC Vero_NP cell_NN viability_NN and_CC growth_NN ._SENT Effects_NNS of_IN Sam_NP B_NP on_IN HSV-1_NP replication_NN and_CC Vero_NP cell_NN viability_NN and_CC growth_NN ._SENT (_( A_NP )_) Inhibitory_JJ effects_NNS of_IN 10_CD muM_NN acyclovir_NN and_CC indicated_JJ concentration_NN of_IN Sam_NP B_NP on_IN HSV-1_NP replication_NN were_VBD determined_VBN by_IN plaque_NN reduction_NN assay_NN ._SENT Each_DT bar_NN represents_VBZ the_DT mean_NN of_IN three_CD independent_JJ experiments_NNS ._SENT (_( B_NP )_) Vero_NP cells_NNS (_( 3.5_CD x_SYM 105_CD in_IN 25-cm2_JJ flasks_NNS )_) were_VBD treated_VBN with_IN medium_NN ,_, 0.1_CD %_NN DMSO_NP ,_, or_CC 25_CD ,_, 50_CD ,_, or_CC 100_CD muM_NN Sam_NP B_NP for_IN 5_CD days_NNS ._SENT Then_RB total_JJ ,_, viable_JJ ,_, and_CC nonviable_JJ cells_NNS were_VBD counted_VBN after_IN staining_VBG with_IN trypan_JJ blue_NN ._SENT Each_DT bar_NN represents_VBZ the_DT mean_NN of_IN three_CD independent_JJ experiments_NNS ._SENT (_( C_NP )_) Vero_NP cells_NNS (_( 5_CD x_SYM 103/well_NP of_IN a_DT 96-well_NN plate_NN )_) were_VBD treated_VBN with_IN Sam_NP B_NP at_IN the_DT indicated_JJ concentrations_NNS or_CC were_VBD treated_VBN without_IN Sam_NP B_NP for_IN 5_CD days_NNS ._SENT Then_RB tritiated_VBN thymidine_NN ,_, tritiated_VBN uridine_NN ,_, or_CC tritiated_VBD leucine_NN was_VBD added_VBN to_TO each_DT well_RB (_( 1_CD muCi/well_NN )_) to_TO detect_VB cell_NN growth_NN ._SENT After_IN a_DT 16-h_NP incubation_NN ,_, the_DT cells_NNS were_VBD harvested_VBN by_IN an_DT automatic_JJ harvester_NN and_CC then_RB radioactivity_NN was_VBD measured_VBN by_IN scintillation_NN counting_NN ._SENT Each_DT bar_NN represents_VBZ the_DT mean_NN of_IN three_CD independent_JJ experiments_NNS ._SENT FIG._NN 5_CD ._SENT |_SYM Kinetics_NP of_IN inhibition_NN of_IN HSV-1_JJ replication_NN by_IN Sam_NP B._NP Kinetics_NP of_IN inhibition_NN of_IN HSV-1_JJ replication_NN by_IN Sam_NP B._NP (_( A_NP )_) Vero_NP cells_NNS (_( 5_CD x_SYM 106_CD )_) were_VBD infected_VBN with_IN HSV-1_NP at_IN an_DT MOI_NP of_IN 3_CD in_IN the_DT presence_NN or_CC absence_NN of_IN acyclovir_NN (_( 10_CD muM_NN )_) or_CC Sam_NP B_NP (_( 25_CD muM_NN )_) ._SENT Treatments_NNS were_VBD as_RB follows_VBZ :_: Sam_NP B_NP was_VBD added_VBN at_IN the_DT same_JJ time_NN as_IN HSV-1_NP ,_, Sam_NP B_NP was_VBD present_JJ after_IN the_DT adsorption_NN period_NN ,_, and_CC Sam_NP B_NP was_VBD present_JJ for_IN 2.5_CD h_NN and_CC removed_VBN before_IN the_DT adsorption_NN phase_NN by_IN washing_VBG the_DT cells_NNS with_IN medium_JJ three_CD times_NNS ._SENT Then_RB cell_NN supernatants_NNS were_VBD collected_VBN at_IN 0_CD ,_, 2_CD ,_, 4_CD ,_, 6_CD ,_, 8_CD ,_, 16_CD ,_, 24_CD ,_, and_CC 36_CD h_NN p.i._NN and_CC the_DT viral_JJ titers_NNS were_VBD determined_VBN by_IN a_DT plaque_NN forming_VBG assay_NN ._SENT Each_DT point_NN represents_VBZ the_DT mean_NN of_IN three_CD independent_JJ experiments_NNS ._SENT (_( B_NP )_) Vero_NP cells_NNS (_( 5_CD x_SYM 106_CD )_) were_VBD infected_VBN with_IN HSV-1_NP (_( MOI_NP ,_, 3_CD )_) ,_, and_CC Sam_NP B_NP (_( 25_CD muM_NN )_) was_VBD added_VBN at_IN the_DT indicated_JJ times_NNS ._SENT Cell_NN supernatants_NNS were_VBD collected_VBN at_IN 25_CD h_NN p.i._NN ,_, and_CC HSV-1_NP titers_NNS were_VBD determined_VBN as_IN described_VBN in_IN Materials_NPS and_CC Methods_NP ._SENT Each_DT bar_NN represents_VBZ the_DT mean_NN of_IN three_CD independent_JJ experiments_NNS ._SENT FIG._NN 6_CD ._SENT |_SYM Effects_NN of_IN Sam_NP B_NP on_IN HSV-1_NP gamma_NN gene_NN expression_NN in_IN Vero_NP cells_NNS detected_VBD by_IN Western_JJ blot_NN analysis_NN and_CC RT-PCR_NP ._SENT Effects_NNS of_IN Sam_NP B_NP on_IN HSV-1_NP gamma_NN gene_NN expression_NN in_IN Vero_NP cells_NNS detected_VBD by_IN Western_JJ blot_NN analysis_NN and_CC RT-PCR_NP ._SENT Vero_NP cells_NNS (_( 5_CD x_SYM 106_CD )_) were_VBD infected_VBN with_IN HSV-1_NP (_( MOI_NP ,_, 3_CD )_) or_CC were_VBD not_RB infected_VBN in_IN the_DT presence_NN or_CC absence_NN of_IN Sam_NP B_NP (_( 25_CD muM_NN )_) ._SENT (_( A_NP )_) Lysates_NP (_( 20_CD mug_NN of_IN protein_NN )_) were_VBD collected_VBN at_IN 16_CD h_NN p.i._NN and_CC run_VB on_IN an_DT SDS-10_NP %_NN PAGE_NN gel_NN and_CC analyzed_VBD by_IN immunoblotting_NN with_IN an_DT anti-gB_NN ,_, -gC_NN ,_, -gD_NNS ,_, -gG_NN ,_, or_CC -ICP5_JJ antibody_NN ._SENT (_( B_LS )_) The_DT total_JJ cellular_JJ RNA_NP was_VBD isolated_VBN from_IN Vero_NP cells_NNS at_IN 16_CD h_NN p.i._NP RT-PCR_NP was_VBD done_VBN as_IN described_VBN in_IN Materials_NPS and_CC Methods_NP ._SENT Following_VBG the_DT reaction_NN ,_, the_DT amplified_VBN product_NN was_VBD run_VBN on_IN a_DT 2_CD %_NN agarose_NN gel_NN ._SENT Lane_NP 1_CD ,_, uninfected_JJ Vero_NP cells_NNS ;_: lane_NN 2_CD ,_, HSV-1-infected_JJ cells_NNS ;_: lane_NN 3_CD ,_, cells_NNS treated_VBN with_IN HSV-1_NP and_CC Sam_NP B_NP at_IN the_DT same_JJ time_NN ;_: lane_NN 4_CD ,_, infected_JJ cells_NNS treated_VBN with_IN Sam_NP B_NP at_IN 12_CD h_NN to_TO 16_CD h_NN p.i._NN The_DT graph_NN indicates_VBZ the_DT ratio_NN of_IN gamma_NN protein_NN or_CC gB_NN mRNA_NN to_TO beta-actin_NN mRNA_NN ._SENT Each_DT bar_NN represents_VBZ the_DT mean_NN of_IN three_CD independent_JJ experiments_NNS ._SENT FIG._NN 7_CD ._SENT |_SYM Effect_NN of_IN Sam_NP B_NP on_IN HSV-1_NP DNA_NP synthesis_NN in_IN Vero_NP cells_NNS detected_VBD by_IN PCR_NP ._SENT Effect_NN of_IN Sam_NP B_NP on_IN HSV-1_NP DNA_NP synthesis_NN in_IN Vero_NP cells_NNS detected_VBD by_IN PCR_NP ._SENT Cells_NNS (_( 5_CD x_SYM 106_CD )_) were_VBD infected_VBN wit_NN 